Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells

被引:22
|
作者
Boichuk, Sergei [1 ,2 ,3 ]
Dunaev, Pavel [1 ]
Mustafin, Ilshat [4 ]
Mani, Shinjit [1 ]
Syuzov, Kirill [1 ]
Valeeva, Elena [2 ]
Bikinieva, Firuza [1 ]
Galembikova, Aigul [1 ]
机构
[1] Kazan State Med Univ, Dept Pathol, Kazan 420012, Russia
[2] Kazan State Med Univ, Cent Res Lab, Kazan 420012, Russia
[3] Russian Med Acad Continuous Profess Educ, Fac Surg, Dept Radiotherapy & Radiol, Moscow 125993, Russia
[4] Kazan State Med Univ, Dept Biochem, Kazan 420012, Russia
基金
俄罗斯基础研究基金会;
关键词
ABC-transporters; paclitaxel; doxorubicin; FGFR-inhibitors; resistance; apoptosis; sensitization; ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; REFRACTORY MULTIPLE-MYELOMA; TO-MESENCHYMAL TRANSITION; DRUG-RESISTANCE; IMATINIB MESYLATE; PHASE-III; NILOTINIB AMN107; ABC TRANSPORTERS; POTENT INHIBITOR;
D O I
10.3390/biomedicines10030601
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The microtubule-targeting agents (MTAs) are well-known chemotherapeutic agents commonly used for therapy of a broad spectrum of human malignancies, exhibiting epithelial origin, including breast, lung, and prostate cancer. Despite the impressive response rates shortly after initiation of MTA-based therapy, the vast majority of human malignancies develop resistance to MTAs due to the different mechanisms. Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox). This was evidenced for the triple-negative breast cancer (TNBC), and gastrointestinal stromal tumor (GIST) cell lines, as well. Indeed, when MDR-overexpressing cancer cells were treated with a combination of BGJ 398 and PTX (or Dox), we observed a significant increase of apoptosis which was evidenced by an increased expression of cleaved forms of PARP, caspase-3, and increased numbers of Annexin V-positive cells, as well. Moreover, BGJ 398 used in combination with PTX significantly decreased the viability and proliferation of the resistant cancer cells. As expected, no apoptosis was found in ABCB1-overexpressing cancer cells treated with PTX, Dox, or BGJ 398 alone. Inhibition of FGFR-signaling by BGJ 398 was evidenced by the decreased expression of phosphorylated (i.e., activated) forms of FGFR and FRS-2, a well-known adaptor protein of FGFR signaling, and downstream signaling molecules (e.g., STAT-1, -3, and S6). In contrast, expression of MDR-related ABC-transporters did not change after BGJ 398 treatment, thereby suggesting an impaired function of MDR-related ABC-transporters. By using the fluorescent-labeled chemotherapeutic agent PTX-Alexa488 (Flutax-2) and doxorubicin, exhibiting an intrinsic fluorescence, we found that BGJ 398 substantially impairs their efflux from MDR-overexpressing TNBC cells. Moreover, the efflux of Calcein AM, a well-known substrate for ABCB1, was also significantly impaired in BGJ 398-treated cancer cells, thereby suggesting the ABCB1 as a novel molecular target for BGJ 398. Of note, PD 173074, a potent FGFR1 and VEGFR2 inhibitor failed to retain chemotherapeutic agents inside ABCB1-overexpressing cells. This was consistent with the inability of PD 173074 to sensitize Tx-R cancer cells to PTX and Dox. Collectively, we show here for the first time that BGJ 398 reverses the sensitivity of MDR-overexpressing cancer cells to certain chemotherapeutic agents due to inhibition of their efflux from cancer cells via ABCB1-mediated mechanism.
引用
收藏
页数:28
相关论文
共 25 条
  • [1] Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells
    Nanayakkara, Amila K.
    Follit, Courtney A.
    Chen, Gang
    Williams, Noelle S.
    Vogel, Pia D.
    Wise, John G.
    SCIENTIFIC REPORTS, 2018, 8
  • [2] Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells
    Amila K. Nanayakkara
    Courtney A. Follit
    Gang Chen
    Noelle S. Williams
    Pia D. Vogel
    John G. Wise
    Scientific Reports, 8
  • [3] FUNCTIONALLY ACTIVE HOMODIMER OF P-GLYCOPROTEIN IN MULTIDRUG-RESISTANT TUMOR-CELLS
    NAITO, M
    TSURUO, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 185 (01) : 284 - 290
  • [4] Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator
    Xu, D
    Ye, DJ
    Fisher, M
    Juliano, RL
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (03): : 963 - 971
  • [5] Characterization of differential interactions between statins and P-glycoprotein in vitro and in multidrug-resistant human tumor cells
    Goard, Carolyn
    Mather, Richard
    Vinepal, Balpreet
    Martirosyan, Anna
    Clendening, James
    Sharom, Frances
    Penn, Linda
    CANCER RESEARCH, 2009, 69
  • [6] DECREASED P-GLYCOPROTEIN EXPRESSION IN MULTIDRUG-SENSITIVE AND MULTIDRUG-RESISTANT HUMAN MYELOMA CELLS INDUCED BY THE CYTOKINE LEUKOREGULIN
    EVANS, CH
    BAKER, PD
    CANCER RESEARCH, 1992, 52 (21) : 5893 - 5899
  • [7] Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells
    Meschini, S
    Marra, M
    Condello, M
    Calcabrini, A
    Federici, E
    Dupuis, ML
    Cianfriglia, M
    Arancia, G
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (06) : 1597 - 1603
  • [8] Prolonged inhibition of P-glycoprotein after exposure to chemotherapeutics increases cell mortality in multidrug resistant cultured cancer cells
    Nanayakkara, Amila K.
    Vogel, Pia D.
    Wise, John G.
    PLOS ONE, 2019, 14 (06):
  • [9] Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells
    Yang, JM
    Vassil, A
    Hait, WN
    BIOCHEMICAL PHARMACOLOGY, 2002, 63 (05) : 959 - 966
  • [10] INFLUX OF DAUNORUBICIN IN MULTIDRUG-RESISTANT EHRLICH ASCITES TUMOR-CELLS - CORRELATION TO EXPRESSION OF P-GLYCOPROTEIN AND EFFLUX - INFLUENCE OF VERAPAMIL
    NIELSEN, D
    MAARE, C
    SKOVSGAARD, T
    BIOCHEMICAL PHARMACOLOGY, 1995, 50 (04) : 443 - 450